- Home
- TULP vs SILO Comparison
TULP vs SILO Comparison
Compare TULP & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TULP | SILO |
|---|---|---|
| Founded | 1990 | 2010 |
| Country | United States | United States |
| Employees | 160 | N/A |
| Industry | Farming/Seeds/Milling | Apparel |
| Sector | Consumer Staples | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.2M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | TULP | SILO |
|---|---|---|
| Price | $3.96 | $0.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 4.3M |
| Earning Date | 02-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.98 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | N/A | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.61 | $0.22 |
| 52 Week High | $4.79 | $1.13 |
Technical Indicators
Market Signals| Indicator | TULP | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 50.66 |
| Support Level | $3.87 | $0.29 |
| Resistance Level | $4.08 | $0.65 |
| Average True Range (ATR) | 0.11 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 72.71 | 19.50 |
Price Performance
Historical ComparisonAbout TULP Bloomia Holdings Inc. Common Stock
Bloomia Holdings Inc is a specialty ag company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.